logo
‘Astonishing': HIV screening policy change normalizes getting tested, experts say

‘Astonishing': HIV screening policy change normalizes getting tested, experts say

Yahoo21-05-2025

AUSTIN (KXAN)– An HIV screening opt-out policy suggested by Central Health, a Travis County Hospital District, helped break the barriers that stemmed from HIV testing– and the numbers were astonishing.
Central Health Senior Director Megan Cermak told KXAN's Tom Miller, that the campaign helps their patients not 'slip through the cracks' because some Illnesses and conditions were not being properly detected until it was too late.
In 2018, the Texas Department of State Health Services (DSHS) identified Central Texas as a 'hot spot' for new HIV diagnoses, Cermak said. A policy change in HIV screenings, however, made a difference to save lives.
Back in the day a positive HIV diagnosis felt like it was the end of the world- especially during the AIDS epidemic in 1995. However, a press release from Central Health stated in 2025, that fear has been shifted due to the accessibility and lifesaving treatment options made available for patients.
'Today, a person with HIV can manage the condition properly with the right care,' said the release.
Although the fear over HIV diagnosis has slightly simmered, life-threatening gaps still continue to exist and a big part of the problem is due to screening.
Central Health's implement in policy changes for HIV screening made efforts to raise awareness and increase testing. The health center created a policy that included HIV testing as part of any blood screenings; mandating HIV screening on blood tests unless patients opted out.
For more than 30 years the CommUnity Care's David Powell Health Center has provided HIV treatment and prevention for all Central Texans, including Travis County, the release said.
Cermak shared with KXAN the impacts Central Health leads through its HIV screening policy and how it combated the stigma around it.
'The HIV screening policy, it's exactly what it sounds, so we make HIV screening a routine part of healthcare. So in your annual exam when you get a blood draw and you're screened for diabetes or cholesterol, you're also screened for HIV,' Cermak said.
Cermak added that this helps patients reduce the stigma around HIV screening because it becomes a routine part of healthcare.
'Patients and the providers have responded so positively because it helps reduce stigma, and it makes what could have been an uncomfortable conversation a normal part of healthcare,' Cermak said.
Cermak told KXAN the outcome from this policy change to implement HIV screenings as part of the routine exams was 'astonishing.'
'HIV screening rates for our Medical Access Program (MAP) patients in Travis County were 64 percent higher than the state average and 84 percent greater than the national average,' Cermak said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hundreds of laid-off CDC employees are being reinstated
Hundreds of laid-off CDC employees are being reinstated

Yahoo

time44 minutes ago

  • Yahoo

Hundreds of laid-off CDC employees are being reinstated

NEW YORK (AP) — More than 460 laid-off employees at the nation's top public health agency received notices Wednesday that they are being reinstated, according to a union representing the workers. The U.S. Department of Health and Human Services confirmed reinstatement notices went out to the former Centers for Disease Control and Prevention employees, but provided few details. About 2,400 CDC employees lost their jobs in a wave of cuts across federal health agencies in early April, according to a tally at the time. Whole CDC programs were essentially shut down, including some focused on smoking, lead poisoning, gun violence, asthma and air quality, and workplace safety and health. The entire office that handles Freedom of Information Act requests was shuttered. Infectious disease programs took a hit, too, including programs that fight outbreaks in other countries, labs focused on HIV and hepatitis in the U.S., and staff trying to eliminate tuberculosis. An estimated 200 of the reinstated workers are based in the CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, HHS officials confirmed. Staffers at a CDC lab that does testing for sexually transmitted diseases are being brought back, said one CDC employee who wasn't authorized to discuss what happened and spoke to The Associated Press on condition of anonymity. Also reinstated are an estimated 150 employees at the CDC's National Center for Environmental Health, including people staffing a lab that works on lead poisoning, according to the union and employees. Layoffs at federal agencies were challenged in lawsuits, with judges in some cases ordering federal agencies to halt terminations of employees. Officials at HHS have never detailed how they made the layoff decisions in the first place. And they did not answer questions about why the notices went out, or how decisions were made about who to bring back. HHS spokesperson Andrew Nixon said the agency was streamlining operations and that 'the nation's critical public health functions remain intact and effective.' "The Trump Administration is committed to protecting essential services — whether it's supporting coal miners and firefighters through NIOSH, safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases,' he said. This is not the first time that employees at the Atlanta-based agency were told they were being terminated only to then be told to come back. After an earlier round of termination notices went out in February, about 180 CDC employees in March were told to come back. __ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Texas to expand psychedelic research with $50M ibogaine investment
Texas to expand psychedelic research with $50M ibogaine investment

Yahoo

timean hour ago

  • Yahoo

Texas to expand psychedelic research with $50M ibogaine investment

AUSTIN (KXAN) — Texas Gov. Greg Abbott is holding a bill signing ceremony Tuesday for legislation that invests $50 million into clinical research of ibogaine — a naturally occurring psychedelic substance that could treat post-traumatic stress disorder, opioid use disorder and other mental health conditions. For years, veterans and others suffering from PTSD have sought ibogaine treatment in Mexico, where the substance is not heavily regulated. In the United States, ibogaine is classified as a Schedule 1 drug, the most restrictive drug category. Other drugs classified under Schedule 1 include psilocybin, LSD and heroin. According to the legislative summary of SB 2308, the implications for those with opioid use disorder are lifechanging; a single administration of ibogaine in a controlled setting has been shown to stop withdrawal symptoms and reduce drug cravings long-term. RELATED: Lawmakers hope to expand medical marijuana program as state bans intoxicating hemp products 'Preliminary reports also suggest benefits in cognitive function, mood regulation, and sleep among individuals with [traumatic brain injury] and PTSD—conditions prevalent among U.S. veterans,' the bill text read. The new legislation will create a program within the Texas Health and Human Services Commission to support Texas-based trials of ibogaine through the FDA. Ibogaine is not currently FDA-approved due to its Schedule 1 classification. SB 2308 will fund research through gifts, grants or donations and will require equal matching funds by the recipients, which will include Texas medical facilities 'equipped for cardiac-intensive monitoring' by a supervising physician, among other qualifications. 'By advancing ibogaine research, Texas has the opportunity to lead in neuroscience innovation, address urgent veteran health needs, and shape the future of mental health treatment nationwide,' the bill text reads. While legislation aimed at easing access to ibogaine moves forward, separate legislation to restrict access to another plant has also progressed. Texas lawmakers sent a bill banning non-medical THC products to Abbott for approval late last month. Still, Texas in recent years has become more open-minded to the use of psychedelic substances in treating mental health conditions. 'There's definitely been a shift in the openness and the receptivity of the field to this type of research,' said Greg Fonzo, Ph.D., co-director of the McGill Center for Psychedelic Research & Therapy at Dell Medical School. 'People who do undergo this treatment process, some of them respond well and have a benefit in terms of symptom reductions and feeling better,' Fonzo told KXAN earlier this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

Yahoo

time6 hours ago

  • Yahoo

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

The Food and Drug Administration has placed a clinical hold on Gilead's (GILD) HIV treatment trials of GS-1720 and/or GS-4182, the company said in a statement. The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182, the company explained. It added, 'Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-1482 are investigational agents and have not been approved anywhere globally. We intend to investigate and pursue the potential of both agents and are committed to working with regulatory authorities to resolve the issues underlying the clinical hold. Gilead has multiple other long-acting oral and injectable investigational HIV treatment combinations under evaluation in clinical and preclinical studies, including combinations with weekly, monthly, quarterly, and twice-yearly dosing. This hold does not impact these combinations or their respective clinical or pre-clinical development programs.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GILD: Disclaimer & DisclosureReport an Issue Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy's Potential as New Standard of Care

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store